AR039358A1 - Formulacion liquida que comprende cetuximab. - Google Patents
Formulacion liquida que comprende cetuximab.Info
- Publication number
- AR039358A1 AR039358A1 ARP020102605A ARP020102605A AR039358A1 AR 039358 A1 AR039358 A1 AR 039358A1 AR P020102605 A ARP020102605 A AR P020102605A AR P020102605 A ARP020102605 A AR P020102605A AR 039358 A1 AR039358 A1 AR 039358A1
- Authority
- AR
- Argentina
- Prior art keywords
- cetuximab
- cancer cells
- egf receptor
- liquid formulation
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
Una formulación farmacéutica líquida que comprende Cetuximab, un buffer fosfato con un pH entre 6 y 8, y un éster de ácido graso de polioxietilen sorbitán. El Cetuximb es un anticuerpo monoclonal quimérico contra el receptor del factor de crecimiento epidérmico (receptor EGF). El bloqueo del receptor EGF por anticuerpos tales como el Cetuximab actúa contra los tumores en varios planos, p. ej. inhibiendo la proliferación de células cancerígenas, reduciendo la angiogénesis mediada por tumores, induciendo la apoptosis de las células cancerígenas e incrementando los efectos tóxicos de la radioterapia y la quimioterapia convencional. Esta formulación líquida que contiene Cetuximab es adecuada para la administración parenteral, se tolera bien y es estable durante un almacenamiento de al menos un ano a temperatura ambiente. Además, tiene una composición simple y no comprende sustancias auxiliares cuestionables desde el punto de vista toxicológico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10133394A DE10133394A1 (de) | 2001-07-13 | 2001-07-13 | Flüssige Formulierung enthaltend Cetuximab |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039358A1 true AR039358A1 (es) | 2005-02-16 |
Family
ID=7691220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102605A AR039358A1 (es) | 2001-07-13 | 2002-07-12 | Formulacion liquida que comprende cetuximab. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040170632A1 (es) |
EP (1) | EP1406658A1 (es) |
JP (1) | JP2004536129A (es) |
KR (1) | KR20040018458A (es) |
CN (1) | CN1231264C (es) |
AR (1) | AR039358A1 (es) |
BR (1) | BR0211060A (es) |
CA (1) | CA2453342A1 (es) |
CZ (1) | CZ2004189A3 (es) |
DE (1) | DE10133394A1 (es) |
HU (1) | HUP0401046A3 (es) |
MX (1) | MXPA04000340A (es) |
PE (1) | PE20030433A1 (es) |
PL (1) | PL364599A1 (es) |
RU (1) | RU2004102395A (es) |
SK (1) | SK862004A3 (es) |
WO (1) | WO2003007988A1 (es) |
ZA (1) | ZA200401161B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3417875T3 (da) * | 2003-02-10 | 2020-08-31 | Biogen Ma Inc | Immunglobulinformulering og fremgangsmåde til fremstilling deraf |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
DE10355904A1 (de) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
AU2005211890B2 (en) * | 2004-02-12 | 2011-07-28 | Merck Patent Gmbh | Highly concentrated liquid formulations of anti-EGFR antibodies |
MXPA06012145A (es) * | 2004-04-27 | 2007-01-31 | Wellstat Biologics Corp | Tratamiento del cancer utilizando virus y camptotecinas. |
JP2008519757A (ja) * | 2004-11-12 | 2008-06-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体の固形物 |
CN101163468A (zh) * | 2005-02-28 | 2008-04-16 | 卫材R&D管理有限公司 | 磺酰胺化合物的新联合用途 |
NZ570381A (en) | 2006-02-09 | 2011-02-25 | Daiichi Sankyo Co Ltd | Anti-cancer pharmaceutical composition |
WO2007128557A1 (en) | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
AU2007307107B2 (en) * | 2006-10-06 | 2011-11-03 | Amgen Inc. | Stable antibody formulations |
TW200833357A (en) * | 2006-10-20 | 2008-08-16 | Amgen Inc | Stable polypeptide formulations |
CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
KR20210024082A (ko) | 2018-06-25 | 2021-03-04 | 제이씨알 파마 가부시키가이샤 | 단백질 함유 수성 액제 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
JPH11507535A (ja) * | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
PT1516628E (pt) * | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
-
2001
- 2001-07-13 DE DE10133394A patent/DE10133394A1/de not_active Withdrawn
-
2002
- 2002-06-18 HU HU0401046A patent/HUP0401046A3/hu unknown
- 2002-06-18 US US10/483,404 patent/US20040170632A1/en not_active Abandoned
- 2002-06-18 BR BR0211060-1A patent/BR0211060A/pt not_active IP Right Cessation
- 2002-06-18 PL PL02364599A patent/PL364599A1/xx unknown
- 2002-06-18 KR KR10-2004-7000530A patent/KR20040018458A/ko not_active Application Discontinuation
- 2002-06-18 WO PCT/EP2002/006696 patent/WO2003007988A1/de not_active Application Discontinuation
- 2002-06-18 CZ CZ2004189A patent/CZ2004189A3/cs unknown
- 2002-06-18 EP EP02751038A patent/EP1406658A1/de not_active Withdrawn
- 2002-06-18 JP JP2003513593A patent/JP2004536129A/ja not_active Withdrawn
- 2002-06-18 MX MXPA04000340A patent/MXPA04000340A/es unknown
- 2002-06-18 SK SK86-2004A patent/SK862004A3/sk not_active Application Discontinuation
- 2002-06-18 RU RU2004102395/15A patent/RU2004102395A/ru not_active Application Discontinuation
- 2002-06-18 CA CA002453342A patent/CA2453342A1/en not_active Abandoned
- 2002-06-18 CN CNB028141059A patent/CN1231264C/zh not_active Expired - Fee Related
- 2002-07-11 PE PE2002000618A patent/PE20030433A1/es not_active Application Discontinuation
- 2002-07-12 AR ARP020102605A patent/AR039358A1/es unknown
-
2004
- 2004-02-12 ZA ZA200401161A patent/ZA200401161B/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0401046A2 (en) | 2006-04-28 |
BR0211060A (pt) | 2004-07-20 |
MXPA04000340A (es) | 2004-05-04 |
KR20040018458A (ko) | 2004-03-03 |
HUP0401046A3 (en) | 2006-11-28 |
DE10133394A1 (de) | 2003-01-30 |
CA2453342A1 (en) | 2003-01-30 |
EP1406658A1 (de) | 2004-04-14 |
SK862004A3 (en) | 2004-07-07 |
PL364599A1 (en) | 2004-12-13 |
ZA200401161B (en) | 2004-10-22 |
US20040170632A1 (en) | 2004-09-02 |
WO2003007988A1 (de) | 2003-01-30 |
CN1527724A (zh) | 2004-09-08 |
JP2004536129A (ja) | 2004-12-02 |
CZ2004189A3 (cs) | 2004-05-12 |
PE20030433A1 (es) | 2003-05-24 |
RU2004102395A (ru) | 2005-05-27 |
CN1231264C (zh) | 2005-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039358A1 (es) | Formulacion liquida que comprende cetuximab. | |
ECSP19078502A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
CO5640082A2 (es) | Compuestos derivados de succinimida heterociclicos fusionados que son moduladores de la funcion del receptor de la hormona nuclear y composiciones farmaceuticas que los contienen | |
PE20190448A1 (es) | Formulacion farmaceutica liquida estable | |
Mora | Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma | |
CO6270340A2 (es) | Formulaciones de anticuerpos anti-cd20 estables a la temperatura y cizalladura | |
PA8583401A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
BR0209777A (pt) | Formulações lìquidas estáveis | |
TW200505890A (en) | Breast cancer-resistant protein inhibitor | |
ATE348635T1 (de) | Injizierbare depotformulierung enthaltend iloperidonkrystalle | |
AR034389A1 (es) | Monohidrato cristalino de bromuro de tiotropio, procedimiento para su preparacion, su utilización para la preparacion de un medicamento, un medicamento que lo contiene, los hidratos cristalinos del bromuro de tiotropio y un procedimiento para preparacion de estos hidratos cristalinos | |
UY27961A1 (es) | Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
CL2008001813A1 (es) | Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04). | |
AR021849A1 (es) | Composiciones y metodos para la inmunoterapia especifica de wt1 | |
CA2454587A1 (en) | Stable lyophilized pharmaceutical formulation of igg antibodies | |
CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
BRPI0515012A (pt) | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso | |
BR0013081A (pt) | Pirimidino-2,4,6-trionas inibidoras de metaloproteinases | |
AU2002364082A1 (en) | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function | |
GT200200188A (es) | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
AR115985A1 (es) | Compuestos de pirazina y usos de los mismos | |
UY29181A1 (es) | Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones | |
GB2380675A (en) | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | |
CY1107906T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |